Sudhir Agrawal to Male
This is a "connection" page, showing publications Sudhir Agrawal has written about Male.
Connection Strength
0.109
-
Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, Agrawal S. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 2013 Apr 01; 41(6):3947-61.
Score: 0.025
-
Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem. 2009 Nov 12; 52(21):6871-9.
Score: 0.020
-
Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, Zhang R, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24; 300(4):853-61.
Score: 0.013
-
Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002 Jul; 21(1):65-72.
Score: 0.012
-
Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet. 2014 May 15; 23(10):2604-17.
Score: 0.007
-
Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One. 2012; 7(5):e38111.
Score: 0.006
-
Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, Kandimalla ER, Agrawal S, Guha C. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One. 2012; 7(1):e29357.
Score: 0.006
-
Ebert CS, Rose AS, Blanks DA, Eapen RP, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC. Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats. Otolaryngol Head Neck Surg. 2007 Aug; 137(2):250-5.
Score: 0.004
-
Blanks DA, Ebert CS, Eapen RP, Zdanski C, Kandimalla ER, Agrawal S, Prazma J. Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats. Otolaryngol Head Neck Surg. 2007 Aug; 137(2):321-6.
Score: 0.004
-
Ebert CS, Rose AS, Patel MR, Hardy SM, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC. The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction. Int J Pediatr Otorhinolaryngol. 2006 Dec; 70(12):2019-26.
Score: 0.004
-
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther. 2006 Jun; 5(6):1585-92.
Score: 0.004
-
Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002 Jul; 21(1):73-80.
Score: 0.003